title: Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.
abstract: Bronchiectatic patients have impaired health-related quality of life (QoL) and are prone to chronic lower respiratory tract infections. We have investigated whether impaired QoL is related to sputum bacteriology. Eighty seven patients with non-cystic fibrosis (non-CF) bronchiectasis, in a stable phase of their illness, completed three QoL measures, underwent a computed tomography (CT) scan and lung function tests, and provided a fresh sputum sample for microscopy and culture. The QoL of patients colonized by Pseudomonas aeruginosa (Pa group) was significantly worse than all other patients grouped together (non-Pa group), and specifically those infected by Haemophilus influenzae (Hi group) or who had no bacterial growth (NG group) (p<0.05), but not those infected by other bacterial species (O group). The Pa group had worse lung function, but no significant differences were found between the groups for forced expiratory volume in one second (FEV1) and peak expiratory flow rate. The Pa group had significantly worse bronchiectasis scores than the O, NG and non-Pa groups, but not the Hi group. There were no significant differences between the groups with respect to the number of infective exacerbations in the last year, but the Pa group had significantly more hospital admissions. Patients infected by P. aeruginosa for more than 3 yrs had significantly worse FEV1 (p<0.03) and bronchiectasis scores (p<0.05) than those infected with P. aeruginosa for less time, but not significantly worse QoL. We conclude that, overall, patients infected with P. aeruginosa have worse quality of life, and that P. aeruginosa is associated with a greater extent of disease and worse lung function. Although patients infected with H. influenzae had extensive bronchiectasis their quality of life was better than the P. aeruginosa infected group.
authors.affiliation: Dept of Thoracic Medicine, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, UK.
authors.forename: C B
authors.initials: CB
authors.lastname: Wilson
authors.forename: P W
authors.initials: PW
authors.lastname: Jones
authors.forename: C J
authors.initials: CJ
authors.lastname: O'Leary
authors.forename: D M
authors.initials: DM
authors.lastname: Hansell
authors.forename: P J
authors.initials: PJ
authors.lastname: Cole
authors.forename: R
authors.initials: R
authors.lastname: Wilson
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000302:isolation & purification*; D001987:Bronchiectasis / Q000000981:diagnostic imaging / Q000382:microbiology* / Q000503:physiopathology*; D015169:Colony Count, Microbial; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D011550:Pseudomonas aeruginosa / Q000235:genetics; D011788:Quality of Life; D012129:Respiratory Function Tests; D013183:Sputum / Q000382:microbiology*; D011795:Surveys and Questionnaires; D014057:Tomography, X-Ray Computed
chemical_list: D000900:Anti-Bacterial Agents